References
- Crystal R G. Chapter 292 : Sarcoidosis. Harrison's Principles of Internal Medicine, 13th edition, K J. Isselbacher, E Braunwald, J D Wilson. McGraw-Hill, Inc. Health Professional Division. 1994; 1679–1684
- Wolbach S B. A new type of cell inclusion, not parasites, associated with disseminated granulomatous disease. Journal of Medical Research 1911; 24: 243–251
- Nickerson D A. Boeck's sarcoid. Report of six cases in which autopsies were made. Archives of Pathology 1937; 24: 19–29
- Brincker H. Coexistence of Sarcoidosis and Malignant Disease: Causality or Coincidence?. Sarcoidosis 1989; 6: 31–43
- Pagano L, Visani G, Ferrara F, Cenacchi A, Bonini A, Equitani F, et al. Contemporaneous Acute Myeloid Leukaemia and Sarcoidosis. Report of Three Cases. Sarcoidosis Vasculitis and Diffuse Lung Diseases 1998; 15: 67–70
- Kataria Y P, Holter J F. Immunology of Sarcoidosis. Clinics in Chest Medicine 1997; 18(4)719–739
- Reich J M, Johnson R E. Sarcoidosis and malignancy (letter). Chest 1995; 108: 1472–1474
- Tunkel A R., Sebastianelli K J., Pandit N, Brody J I. Development of 5q- Myelodysplasia in a Patient with Sarcoidosis. American Journal of Hematology 1990; 34: 225–227
- van Furth R, van Zwet T L. Cytochemical, functional and proliferative characteristics of promonocytes and monocytes from patients with monocytic leukaemia. Blood 1983; 62: 298–304
- Zwierzina H, Sepp N, Ringler E, Schmalzl F. Delayed maturation of skin window macrophages in myelodysplastic syndromes. Leukemia Research 1989; 13(6)433–437
- Felzmann T, Gisslinger H, Ludwig H. Immunological findings in patients with myelodysplastic syndrome. Leukemia and Lymphoma 1994; 15(3–4): 201–208
- Tanoue L T, Elias J A. Chapter 20. Systemic Sarcoidosis. Textbook of Pulmonary Disease, 6th Edition, G L Baum, J D Crapo, B R Celli, J B Karlinsky. Lippincott-Raven Press. 1998; Vol. I: 407–430
- Yokose Ogata N. K., Ito T, An E, Tamura H, Hamaguchi H, et al. Elevated plasma soluble interleukin-2 receptor level correlated with defective natural killer and CD8+ T-cells in myelodysplastic syndrome. Leukemia Research 1994; 18(10)777–782
- Hamblin T J. Immunological abnormalities in myelodysplastic syndrome. Hematology Oncology Clinics in North America 1992; 6: 571–586
- Nagai K, Kohno T, Chen Y X, Tsushima H, Mori H, Nakamura H, et al. Diagnostic Criteria for Hypocellular Acute Leukemia: a clinical entity distinct from overt Acute Leukemia and Myelodysplastic Syndrome. Leukemia Research 1996; 20(7)563–574
- Tuzuner Cox N. C., Rowe J M, Watrons D, Bennett J M. Hypocellular myelodysplastic syndrome (MDS): new proposals. British Journal of Haematology 1905; 91: 612–617
- Geary C G, Marsh J CW, Gordon-Smith E C. Hypo-plastic myelodysplasia (MDS): Correspondence. British Journal of Haematology 1996; 94: 579–580
- Kitagawn M, Kamiyama R, Takemura T, Kasuga T. Bone marrow analysis of the myelodysplastic syndrome: histological and immunohistochemical features related to the evolution of overt leukemia. Virchows Archives (B). Cell Pathology (including Molecular Pathology) 1989; 57(1)47–53
- Ohyushiki J H, Iwabuchi A, Toyama K. Clinical aspects, cytogenetics and disease evolution in myelodysplastic syndromes. Leukemia and Lymphoma 1996; 23: 409–415
- Teramura M, Kobayashi S, Iwabe K, Yoshinaga K, Mizoguchi H. Mechanism of action of antithymocyte globulin in the treatment of aplastic anaemia: in vitro evidence for the presence of immunosuppressive mechanism. British Journal of Haematology 1997; 96: 80–84